The Consolidated Appropriations Act, signed into law on February 3, 2026, avoided another government shutdown. But notably for the US Food and Drug Administration (FDA) and drug developers, it also codified FDA’s long-standing approach toward the scope of orphan drug exclusivity that had become a subject of litigation in recent years. The Orphan Drug Act of 1983 was intended to incentivize the development of drugs for rare diseases.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Natasha Leskovsek
Better Late Than Never? FDA Receives Long-Awaited Statutory Fix for Orphan Drug Exclusivity in Recent Appropriations Act
The Consolidated Appropriations Act, signed into law on February 3, 2026, avoided another government shutdown. But notably for the US Food and Drug Administration (FDA) and drug developers, it also codified FDA's long-standing approach toward the...
FDA’s Rare Disease Evidence Principles Process Provides Guidance for Applications Supported by a Single Pivotal Trial | JD Supra
On September 3, 2025, the US Food and Drug Administration (FDA) announced a new process to support the development of drugs intended to treat rare genetic diseases. The Rare Disease Evidence Principles (RDEP) process offers drug sponsors increased clarity on what constitutes “substantial evidence” of effectiveness for certain rare disease drug treatments, recognizing the unique challenges facing rare disease drug development, i.e., difficulties in enrolling large and randomized clinical trials.
Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings | JD Supra
Applied Therapeutics, a clinical-stage biopharmaceutical company, is under heightened scrutiny following the issuance of a November 2024 Warning Letter1 from the US Food and Drug Administration (FDA) on the heels of a routine preapproval bioresearch monitoring (BIMO) inspection.2 FDA’s BIMO program is designed to ensure the integrity of data submitted to FDA, and to protect the rights, safety and welfare of research participants.
FDA Finalizes Guidance on Use of Part 11 Electronic Systems, Records and Signatures in Clinical Investigations | JD Supra
On October 1, 2024, the US Food and Drug Administration (FDA) finalized its guidance on the use of electronic records in clinical investigations of drugs, devices, biologics, foods, tobacco products and new animal drugs. The guidance is intended to assist a wide range of stakeholders – including sponsors, clinical investigators, institutional review boards (IRBs) and contract research organizations (CROs) – on good clinical practice compliance.
FDA Finalizes Guidance on Use of Part 11 Electronic Systems, Records and Signatures in Clinical Investigations
On October 1, 2024, the US Food and Drug Administration (FDA) finalized its guidance on the use of electronic records in clinical investigations of drugs, devices, biologics, foods, tobacco products and new animal drugs. The guidance is intended to assist a wide range of stakeholders – including sponsors, clinical investigators, institutional review boards (IRBs) and contract research organizations (CROs) – on good clinical practice compliance.
FTC Issues Antitrust Warning Against ‘Improper’ Orange Book Patent Listings | JD Supra
The US Federal Trade Commission (FTC) recently issued a policy statement “to put market participants on notice that the FTC intends to scrutinize improper Orange Book listings” and take “actions against companies and individuals that improperly list patents in the Orange Book.” Aggressive and broad in scope, the FTC’s statement: Suggests the FTC views “improper” Orange Book listings to be essentially per se antitrust violations, unlawful regardless of the reasonableness of the listing.
FDORA’s Changes to the FDA Accelerated Approval Program | JD Supra
February 1, 2023 Natasha Leskovsek, Sonia Nath, Zimu Yang Cooley LLP + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: Enacted on December 29, 2022, the Consolidated Appropriations Act (the year-end omnibus spending bill) includes the Food and Drug Omnibus Reform Act (FDORA), which enhances the Food and Drug Administration’s authority in several key areas.
FDA Doubles Down on Its Pre-Catalyst Stance on Orphan Drug Exclusivity | JD Supra
On January 24, 2023, the Food and Drug Administration published a notice in the Federal Register to “address the uncertainty” created by the US Court of Appeals for the Eleventh Circuit’s September 30, 2021, decision in Catalyst Pharms., Inc. v. Becerra.
FDA Unveils Considerations for Rescinding Breakthrough Therapy Designation | JD Supra
On June 24, 2022, the US Food and Drug Administration issued a draft guidance document on the Considerations for Rescinding Breakthrough Therapy Designation. The guidance explains how the FDA may rescind a drug or biologic candidate’s breakthrough therapy designation during its development (this guidance does not apply to medical devices1). The agency is accepting public comments on this guidance through August 23, 2022. What is breakthrough therapy designation (BTD)?
Liquid Biopsy Technology: FDA's Latest Guidance Supports Several Uses Of CtDNA In Clinical Trials, But Not (yet) As Surrogate Clinical Endpoint
On May 3, 2022, the US Food and Drug Administration issued a draft guidance document on the Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development. The guidance is aimed at helping developers use circulating tumor DNA (ctDNA) as a biomarker in early-stage solid tumor clinical trials and in seeking market approval for in vitro diagnostic assays.
FDA Releases Draft Guidance On Development Of Genome Editing And CAR T Therapies
On March 15, 2022, the US Food and Drug Administration issued a pair of draft guidance documents in the gene therapy space. The first, which is specific to gene therapies incorporating genome editing (GE), was aimed at helping developers of these novel therapies better understand what the FDA is looking for in Investigational New Drug (IND) submissions to control for the risks that the agency is most concerned with for these therapies.
FDA Releases Draft Guidance on Development of Genome Editing and CAR T Therapies | JD Supra
On March 15, 2022, the US Food and Drug Administration issued a pair of draft guidance documents in the gene therapy space. The first, which is specific to gene therapies incorporating genome editing (GE), was aimed at helping developers of these novel therapies better understand what the FDA is looking for in Investigational New Drug (IND) submissions to control for the risks that the agency is most concerned with for these therapies.
DOJ Previews Enforcement Policies Aimed At Clinical Trial Fraud
United States: DOJ Previews Enforcement Policies Aimed At Clinical Trial Fraud 27 December 2021 by Andrew D. Goldstein , Daniel Grooms , Zachary R. Hafer , Natasha Leskovsek , Sonia Nath and Vince Sampson Cooley LLP Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com.
COVID-19: Weekly Life Sciences Digest – Testing Kits For COVID-19 - Coronavirus (COVID-19) - United States
This week, we take a closer look at the development of testing kits in the response to the COVID-19 crisis. Testing, testing, 1, 2, 3. First, it's worth clarifying what we mean by "testing kits".
COVID-19: Weekly Life Sciences Digest – Guidance For Industry In EU, UK And US - Coronavirus (COVID-19) - Worldwide
Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice): Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below. Mondaq has a "free to view" business model.
COVID-19: Weekly Life Sciences Digest - Guidance for Industry in EU, UK and US | Lexology
This week, we look at guidance for industry in the EU, UK and US in respect of medical supplies considered central to the fight against COVID-19: medical devices, medicines, PPE and hand sanitizer. This blog considers the introduction of new infrastructure and the relaxation of existing regulatory requirements, and builds on our previous blogs since the beginning of the crisis, including overall considerations for pivot of manufacture and past EU and UK guidance.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Natasha
Contact Natasha, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack